BRCA1/2 mutations, including large genomic rearrangements, among unselected ovarian cancer patients in Korea.
- Author:
Do Hoon KIM
1
;
Chi Heum CHO
;
Sun Young KWON
;
Nam Hee RYOO
;
Dong Seok JEON
;
Wonmok LEE
;
Jung Sook HA
Author Information
- Publication Type:Original Article
- Keywords: Mutation; Genes; Neoplasms; Ovary; Korea
- MeSH: Breast; Carcinoma, Neuroendocrine; Codon, Nonsense; Female; Genetic Testing; Humans; Korea*; Multiplex Polymerase Chain Reaction; Ovarian Neoplasms*; Ovary; Polymerase Chain Reaction; Prevalence
- From:Journal of Gynecologic Oncology 2018;29(6):e90-
- CountryRepublic of Korea
- Language:English
- Abstract: OBJECTIVE: We performed small-scale mutation and large genomic rearrangement (LGR) analysis of BRCA1/2 in ovarian cancer patients to determine the prevalence and the characteristics of the mutations. METHODS: All ovarian cancer patients who visited a single institution between September 2015 and April 2017 were included. Sanger sequencing, multiplex ligation-dependent probe amplification (MLPA), and long-range polymerase chain reaction (PCR) were performed to comprehensively study BRCA1/2. The genetic risk models BRCAPRO, Myriad, and BOADICEA were used to evaluate the mutation analysis. RESULTS: In total, 131 patients were enrolled. Of the 131 patients, Sanger sequencing identified 16 different BRCA1/2 small-scale mutations in 20 patients (15.3%). Two novel nonsense mutations were detected in 2 patients with a serous borderline tumor and a large-cell neuroendocrine carcinoma. MLPA analysis of BRCA1/2 in Sanger-negative patients revealed 2 LGRs. The LGRs accounted for 14.3% of all identified BRCA1 mutations, and the prevalence of LGRs identified in this study was 1.8% in 111 Sanger-negative patients. The genetic risk models showed statistically significant differences between mutation carriers and non-carriers. The 2 patients with LGRs had at least one blood relative with breast or ovarian cancer. CONCLUSION: Twenty-two (16.8%) of the unselected ovarian cancer patients had BRCA1/2 mutations that were detected through comprehensive BRCA1/2 genetic testing. Ovarian cancer patients with Sanger-negative results should be considered for LGR detection if they have one blood relative with breast or ovarian cancer. The detection of more BRCA1/2 mutations in patients is important for efforts to provide targeted therapy to ovarian cancer patients.
